Relay Therapeutics Q3 2026 net loss widens 10% to $81.75 million
RLAY•Relay Therapeutics’ third-quarter 2026 net loss widened 10% year over year to $81.75 million. Cash, cash equivalents and investments totaled $848.6 million at September 30, with funding expected to cover operating and capital requirements into 2029.
1. Quarterly results and outlook
Relay Therapeutics’ third-quarter 2026 net loss widened 10% year over year to $81.75 million. Research and development expenses rose 13% to $77.14 million, primarily due to clinical-trial costs and nonrecurring lease-termination costs. The company had $848.6 million in cash, cash equivalents and investments at September 30, which it expects to cover operating and capital requirements into 2029. Enrollment in the Phase 3 ReDiscover-2 breast cancer trial is expected to finish in mid-2027, approximately one year faster than recent benchmarks.
